Trial Profile
TBTC Study 33. An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Isoniazid (Primary) ; Rifapentine (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Acronyms iAdhere
- 23 Feb 2023 Results assessing the patterns of symptom development and identify SDR and associated factors in patients on 3 months of weekly rifapentine plus isoniazid, published in the Clinical Infectious Diseases.
- 18 May 2016 Results of post-hoc analysis of two phase III studies (PREVENT TB and iAdhere) presented at the 112th International Conference of the American Thoracic Society
- 01 Dec 2012 Additional lead trial centre added as reported by European Clinical Trials Database record.